Browsing by Author "Antmen, Bulent"

Now showing 1 - 2 of 2

Cost of hemophilia A in Turkey: an economic disease burden analysis
(2021) Malhan, Simten; Oksuz, Ergun; Antmen, Bulent; Ar, Muhlis Cem; Balkan, Can; Kavakli, Kaan; 0000-0002-5723-5965; 34355649; K-8238-2012
Objective: Hemophilia A is the second most common bleeding disorder causing patients to have lifelong follow-up and treatment. Despite being a rare disease, hemophilia A has a high economic burden on individuals and the public. The purpose of this study was to estimate the total disease cost of hemophilia A in Turkey. Materials and Methods: Data used in this analysis were collected through literature review, including studies conducted in Turkey in December 2018. A disease burden analysis was performed by modeling hemophilia A-related costs among patients, their relatives, and the social security system. Two expert panels were held to evaluate real-world data sources and to provide further information. All direct medical and non-medical costs were calculated annually from the Social Security Institution of the Republic of Turkey perspective, while indirect costs were estimated from the patient and community perspective. Results: For the calendar year of 2018, the number of hemophilia A patients in Turkey were estimated to be 5,055, with an average weight of 64.7 kg. The average annual direct medical, direct non-medical, and indirect costs of hemophilia A were calculated as euro93,268 ($109,286; (sic)502,717), euro2,533 ($2,968; (sic)13,655), and euro7,957 ($9,323; (sic)42,888) per patient, respectively, with a total annual cost of euro103,759 ($121,578; (sic)559,259). For the management of patients with inhibitors (4.9%), the average annual total cost was calculated to be euro325,439 ($381,330; (sic)1,754,117) per patient. The total annual disease burden of hemophilia A in 2018 was estimated to be about euro524 million ($614 million; (sic)2.82 billion), which corresponded to 1.6% of the total health expenditure in Turkey. Conclusion: The most important reason hemophilia A has a significant economic burden in Turkey is that replacement therapy is expensive. The major cost contributor was identified as factor replacement therapy. With inhibitor development, the average annual cost increased more than 3-fold.
Serum Fas and Fas Ligand levels in childhood acute lymphoblastic leukemias
(2019) Arslan, Alev; Antmen, Bulent
Purpose: The aim of this study was to investigate the Fas and Fas Ligand levels of cell membrane receptors that play a role in understanding the mechanism of apoptosis in childhood acute lymphoblastic leukemia (ALL). Materials and Methods: We investigated serum Fas and Fas Ligand levels by using ELISA method in childhood acute leukemias. Twenty-nine cases with acute lymphoblastic leukemia and twenty-seven healthy children included the study. We investigated serum Fas and Fas Ligand levels at the time of diagnosis from peripheral blood samples. Results: Serum Fas levels of patients were median 63 pg/mL (min 15- max 690 pg/mL) and in the control group were median 37 pg/mL (min 8- max 67 pg/mL). Fas Ligand levels of patients were median 0.18 ng/mL (min 0- max 2.1 ng/mL) and in the control group median 0.1 ng/mL (min 0- max 4 ng/mL). The comparison of the mean values of Fas levels in acute leukemia patients groups and control group have shown important difference as statistically, but Fas Ligand levels were similar. Fas levels in T-ALL patients according to immunophenotypes were statistically higher than B-ALL . The Fas levels of patients who had relapsed were statistically higher than patients in remission. Conclusion: Serum Fas levels could be a useful prognostic marker in ALL patients follow up.